Alector Inc (ALEC)

$1.49 +0.11 (7.97%)
Market Cap 137.99M
Revenue (ttm) 100.56M
Net Income (ttm) -119.05M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -118.39%
Debt to Equity Ratio 0.10
Volume 398,500
Avg Vol 934,836
Day's Range N/A - N/A
Shares Out 99.99M
Stochastic %K 39%
Beta 0.71
Analysts Sell
Price Target $5.00

Company Profile

Alector, Inc., a late-stage clinical biotechnology company, develops therapies that is focused on counteracting the devastating progression of neurodegenerative diseases. The company's products under development include Latozinemab (AL001), an investigational human recombinant monoclonal antibody designed to elevate progranulin (PGRN), a protein encoded by the granulin (GRN) gene that regulates lysosomal function, neuronal survival, and inflammation in the brain. Its lead PGRN-elevating candidat...

Industry: Biotechnology
Sector: Healthcare
Phone: 415 231 5660
Address:
131 Oyster Point Boulevard, Suite 600, South San Francisco, United States
RobbyAxelrod1
RobbyAxelrod1 Jun. 18 at 2:23 PM
$AVXL Soon $ALEC as well.
0 · Reply
QuiverQuant
QuiverQuant Jun. 13 at 8:49 PM
Neil Berkley Appointed Interim Chief Financial Officer at Alector, Inc. Following Marc Grasso’s Departure Read more on $ALEC: https://www.quiverquant.com/news/Neil+Berkley+Appointed+Interim+Chief+Financial+Officer+at+Alector%2C+Inc.+Following+Marc+Grasso%E2%80%99s+Departure
0 · Reply
manymore
manymore Jun. 12 at 11:25 AM
$ALEC so little action on this ticker - it is not for everyone, but if the reward wins over the risk, the reward will be enormous
0 · Reply
revueltoL
revueltoL Jun. 4 at 2:58 PM
$ALEC if I had to bet on the strongest recovery among the biotechs I follow, this would be the one. I’m never all in, but I’m confident its story will eventually resonate…
1 · Reply
TWITLIEDETECTOR
TWITLIEDETECTOR Jun. 3 at 1:04 AM
$ALEC Look at the chart, it's on a run.... probably cool down but hard to say when.... company in P3 with this play should be sitting at $5
0 · Reply
RunnerSignals
RunnerSignals Jun. 2 at 8:56 PM
Comeback Kings $QBTS $JBLU $QUBT $ALEC $FROG dipped hard midday but stormed back strong into the close. Nice turnaround
0 · Reply
TimRegan_WTR
TimRegan_WTR May. 29 at 5:50 PM
$ABBV $ALEC $DNLI $NVS $TAK
0 · Reply
research_WTR
research_WTR May. 29 at 5:42 PM
TREM2 Agonists: A New Frontier in Neurodegeneration Despite past clinical setbacks, Sanofi’s $470–$600M acquisition of Vigil Neuroscience signals renewed confidence in TREM2 as a key neuroinflammation target in Alzheimer’s and other disorders. 🔹 TREM2 helps microglia clear toxic proteins and regulate inflammation in the CNS 🔹 Past mAb candidates (ALEC/ABBV, DNLI) failed in trials due to lack of efficacy or safety concerns 🔹 Vigil’s oral TREM2 agonist (VG-3927) showed strong Phase 1 data and heads to Phase 2 in 2H25 🔹 Sanofi’s support may reshape the future of microglia-targeted neurotherapies Subscribe at our website to follow along with Robert Sassoon! $ALEC $ABBV $DNLI $TAK $NVS
0 · Reply
revueltoL
revueltoL May. 28 at 4:23 PM
$ALEC this will be huge, not ‘yuuuge’ as T says..the ‘real’ huge..
0 · Reply
RobbyAxelrod1
RobbyAxelrod1 May. 28 at 2:57 PM
$ALEC In phase 3 results 4th qtr.
0 · Reply
Latest News on ALEC
Alector Provides Executive Leadership Update

Jun 13, 2025, 4:05 PM EDT - 11 days ago

Alector Provides Executive Leadership Update

Alector to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

Jun 3, 2025, 8:00 AM EDT - 21 days ago

Alector to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

Alector Reports First Quarter 2025 Financial Results and Provides Business Update

May 8, 2025, 4:05 PM EDT - 6 weeks ago

Alector Reports First Quarter 2025 Financial Results and Provides Business Update

Alector to Participate in Upcoming Healthcare Conferences

May 6, 2025, 8:00 AM EDT - 7 weeks ago

Alector to Participate in Upcoming Healthcare Conferences

Alector Announces Completion of Enrollment in the PROGRESS-AD Phase 2 Clinical Trial of AL101/GSK4527226 in Individuals with Early Alzheimer's Disease

Apr 17, 2025, 8:00 AM EDT - 2 months ago

Alector Announces Completion of Enrollment in the PROGRESS-AD Phase 2 Clinical Trial of AL101/GSK4527226 in Individuals with Early Alzheimer's Disease

GSK

Alector, Inc. (ALEC) Q4 2024 Earnings Call Transcript

Feb 27, 2025, 1:09 AM EST - 4 months ago

Alector, Inc. (ALEC) Q4 2024 Earnings Call Transcript

Alector Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Feb 26, 2025, 4:05 PM EST - 4 months ago

Alector Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Alector to Host Fourth Quarter and Full-Year 2024 Earnings Conference Call

Feb 19, 2025, 4:05 PM EST - 4 months ago

Alector to Host Fourth Quarter and Full-Year 2024 Earnings Conference Call

Alector Reports on Recent Progress and Outlines Strategic Priorities for 2025

Jan 13, 2025, 8:00 AM EST - 5 months ago

Alector Reports on Recent Progress and Outlines Strategic Priorities for 2025

Neurology-Focused Alector Downgraded On Failed Alzheimer's Study, BofA Securities Highlights Lack Of Catalysts

Dec 4, 2024, 2:20 PM EST - 7 months ago

Neurology-Focused Alector Downgraded On Failed Alzheimer's Study, BofA Securities Highlights Lack Of Catalysts

Alector/AbbVie-Partnered Alzheimer's Drug Disappoints In Mid-Stage Study; Alector Lays Off 17% Of Workforce

Nov 26, 2024, 10:29 AM EST - 7 months ago

Alector/AbbVie-Partnered Alzheimer's Drug Disappoints In Mid-Stage Study; Alector Lays Off 17% Of Workforce

Alector Announces Results from AL002 INVOKE-2 Phase 2 Trial in Individuals with Early Alzheimer's Disease and Provides Business Update

Nov 25, 2024, 4:05 PM EST - 7 months ago

Alector Announces Results from AL002 INVOKE-2 Phase 2 Trial in Individuals with Early Alzheimer's Disease and Provides Business Update

Alector Secures Flexible Credit Facility for Up to $50 Million From Hercules Capital

Nov 14, 2024, 4:05 PM EST - 7 months ago

Alector Secures Flexible Credit Facility for Up to $50 Million From Hercules Capital

Alector Reports Third Quarter 2024 Financial Results and Provides Business Update

Nov 6, 2024, 4:05 PM EST - 8 months ago

Alector Reports Third Quarter 2024 Financial Results and Provides Business Update

Alector, Inc. (ALEC) Q2 2024 Earnings Call Transcript

Aug 8, 2024, 11:53 PM EDT - 11 months ago

Alector, Inc. (ALEC) Q2 2024 Earnings Call Transcript

Alector Reports Second Quarter 2024 Financial Results and Provides Business Update

Aug 7, 2024, 4:05 PM EDT - 11 months ago

Alector Reports Second Quarter 2024 Financial Results and Provides Business Update

Alector to Host Mid-Year Earnings Conference Call

Jul 31, 2024, 4:05 PM EDT - 11 months ago

Alector to Host Mid-Year Earnings Conference Call

Alector Presents Baseline Characteristics for INVOKE-2 Phase 2 Clinical Trial of AL002 at the Alzheimer's Association International Conference® 2024 (AAIC®)

Jul 28, 2024, 8:05 AM EDT - 11 months ago

Alector Presents Baseline Characteristics for INVOKE-2 Phase 2 Clinical Trial of AL002 at the Alzheimer's Association International Conference® 2024 (AAIC®)

Alector to Present Data on Pipeline Focus Areas at the Alzheimer's Association International Conference® (AAIC®) 2024

Jul 23, 2024, 7:00 AM EDT - 1 year ago

Alector to Present Data on Pipeline Focus Areas at the Alzheimer's Association International Conference® (AAIC®) 2024

Alector to Host Virtual Research and Development Event Highlighting Alector Brain Carrier Blood-Brain Barrier Technology Platform

Jun 10, 2024, 7:00 AM EDT - 1 year ago

Alector to Host Virtual Research and Development Event Highlighting Alector Brain Carrier Blood-Brain Barrier Technology Platform

Alector, Inc. (ALEC) Q4 2023 Earnings Call Transcript

Feb 27, 2024, 11:23 PM EST - 1 year ago

Alector, Inc. (ALEC) Q4 2023 Earnings Call Transcript

Alector Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Feb 27, 2024, 4:05 PM EST - 1 year ago

Alector Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Alector to Host Fourth Quarter and Full-Year 2023 Earnings Call

Feb 20, 2024, 4:05 PM EST - 1 year ago

Alector to Host Fourth Quarter and Full-Year 2023 Earnings Call

Alector Announces First Patient Dosed in PROGRESS-AD Phase 2 Clinical Trial of AL101/GSK4527226 in Patients with Early Alzheimer's Disease

Feb 8, 2024, 7:00 AM EST - 1 year ago

Alector Announces First Patient Dosed in PROGRESS-AD Phase 2 Clinical Trial of AL101/GSK4527226 in Patients with Early Alzheimer's Disease

FDA Grants Latozinemab Breakthrough Therapy Designation for Frontotemporal Dementia Due to a Progranulin Gene Mutation (FTD-GRN)

Feb 7, 2024, 7:00 AM EST - 1 year ago

FDA Grants Latozinemab Breakthrough Therapy Designation for Frontotemporal Dementia Due to a Progranulin Gene Mutation (FTD-GRN)

Alector Announces Closing of Public Offering

Jan 19, 2024, 9:20 AM EST - 1 year ago

Alector Announces Closing of Public Offering

Alector: Q4 2024 Data Release Could Provide Major Shift For Valuation

Jan 17, 2024, 5:32 PM EST - 1 year ago

Alector: Q4 2024 Data Release Could Provide Major Shift For Valuation

Alector Announces Pricing of Public Offering of Common Stock

Jan 17, 2024, 8:54 AM EST - 1 year ago

Alector Announces Pricing of Public Offering of Common Stock

Alector Announces Proposed Public Offering of Common Stock

Jan 16, 2024, 4:01 PM EST - 1 year ago

Alector Announces Proposed Public Offering of Common Stock

Alector: Good Data, Huge Cash, No Near Term Catalyst

Jan 16, 2024, 11:12 AM EST - 1 year ago

Alector: Good Data, Huge Cash, No Near Term Catalyst

Alector to Host Two Virtual Research and Development Events Highlighting TREM2 and Progranulin Programs

Nov 28, 2023, 7:00 AM EST - 1 year ago

Alector to Host Two Virtual Research and Development Events Highlighting TREM2 and Progranulin Programs

Alector to Participate in the Stifel Healthcare Conference

Nov 8, 2023, 7:00 AM EST - 1 year ago

Alector to Participate in the Stifel Healthcare Conference

Alector Reports Third Quarter 2023 Financial Results and Provides Business Update

Nov 7, 2023, 4:05 PM EST - 1 year ago

Alector Reports Third Quarter 2023 Financial Results and Provides Business Update

Alector Announces Achievement of Target Enrollment in the Pivotal INFRONT-3 Phase 3 Clinical Trial of Latozinemab in Individuals with Frontotemporal Dementia Due to a Progranulin Gene Mutation (FTD-GRN)

Oct 27, 2023, 7:00 AM EDT - 1 year ago

Alector Announces Achievement of Target Enrollment in the Pivotal INFRONT-3 Phase 3 Clinical Trial of Latozinemab in Individuals with Frontotemporal Dementia Due to a Progranulin Gene Mutation (FTD-GRN)

Alector, Inc. (ALEC) Q2 2023 Earnings Call Transcript

Aug 4, 2023, 9:45 AM EDT - 2 years ago

Alector, Inc. (ALEC) Q2 2023 Earnings Call Transcript

Alector to Participate in the Goldman Sachs 44th Annual Global Healthcare Conference

Jun 6, 2023, 7:00 AM EDT - 2 years ago

Alector to Participate in the Goldman Sachs 44th Annual Global Healthcare Conference

Alector Reports First Quarter 2023 Financial Results and Provides Business Update

May 4, 2023, 4:05 PM EDT - 2 years ago

Alector Reports First Quarter 2023 Financial Results and Provides Business Update

Alector to Participate in the BofA Securities 2023 Healthcare Conference

May 2, 2023, 7:00 AM EDT - 2 years ago

Alector to Participate in the BofA Securities 2023 Healthcare Conference

Alector Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

Feb 28, 2023, 4:05 PM EST - 2 years ago

Alector Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

Alector: Trading At Cash Despite Late Stage CNS Pipeline

Feb 3, 2023, 2:13 PM EST - 2 years ago

Alector: Trading At Cash Despite Late Stage CNS Pipeline

Alector Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Dec 8, 2022, 4:30 PM EST - 2 years ago

Alector Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Alector Presents Results from First-in-Human Phase 1 Study of AL101 for the Treatment of Neurodegenerative Diseases

Nov 29, 2022, 11:05 AM EST - 2 years ago

Alector Presents Results from First-in-Human Phase 1 Study of AL101 for the Treatment of Neurodegenerative Diseases

Alector Announces Promotion of Clare Hunt to Chief People Officer

Oct 13, 2022, 8:00 AM EDT - 2 years ago

Alector Announces Promotion of Clare Hunt to Chief People Officer

Alector: Advancement Of Third Alzheimer's Drug Brings About Huge Potential

Oct 4, 2022, 5:42 AM EDT - 2 years ago

Alector: Advancement Of Third Alzheimer's Drug Brings About Huge Potential

MDA Breakout Stocks Week 40 - October 2022: Short-Term Picks To Give You An Edge

Oct 3, 2022, 9:09 AM EDT - 2 years ago

MDA Breakout Stocks Week 40 - October 2022: Short-Term Picks To Give You An Edge

AAPL CAT CELH CLFD CVX DOW ENPH

Alector Initiates Phase 1 Clinical Trial of AL044 for the Treatment of Alzheimer's Disease (AD)

Sep 12, 2022, 7:00 AM EDT - 3 years ago

Alector Initiates Phase 1 Clinical Trial of AL044 for the Treatment of Alzheimer's Disease (AD)

Alector: Potential In Neurology And Cancer Treatments

Jun 14, 2022, 1:29 PM EDT - 3 years ago

Alector: Potential In Neurology And Cancer Treatments

Alector to Participate in the Goldman Sachs 43rd Annual Global Healthcare Conference

Jun 8, 2022, 7:00 AM EDT - 3 years ago

Alector to Participate in the Goldman Sachs 43rd Annual Global Healthcare Conference

Alector Reports Inducement Grants as permitted by the Nasdaq Listing Rules

May 27, 2022, 4:30 PM EDT - 3 years ago

Alector Reports Inducement Grants as permitted by the Nasdaq Listing Rules

Alector to Participate at the BofA Securities 2022 Healthcare Conference

May 4, 2022, 7:00 AM EDT - 3 years ago

Alector to Participate at the BofA Securities 2022 Healthcare Conference

RobbyAxelrod1
RobbyAxelrod1 Jun. 18 at 2:23 PM
$AVXL Soon $ALEC as well.
0 · Reply
QuiverQuant
QuiverQuant Jun. 13 at 8:49 PM
Neil Berkley Appointed Interim Chief Financial Officer at Alector, Inc. Following Marc Grasso’s Departure Read more on $ALEC: https://www.quiverquant.com/news/Neil+Berkley+Appointed+Interim+Chief+Financial+Officer+at+Alector%2C+Inc.+Following+Marc+Grasso%E2%80%99s+Departure
0 · Reply
manymore
manymore Jun. 12 at 11:25 AM
$ALEC so little action on this ticker - it is not for everyone, but if the reward wins over the risk, the reward will be enormous
0 · Reply
revueltoL
revueltoL Jun. 4 at 2:58 PM
$ALEC if I had to bet on the strongest recovery among the biotechs I follow, this would be the one. I’m never all in, but I’m confident its story will eventually resonate…
1 · Reply
TWITLIEDETECTOR
TWITLIEDETECTOR Jun. 3 at 1:04 AM
$ALEC Look at the chart, it's on a run.... probably cool down but hard to say when.... company in P3 with this play should be sitting at $5
0 · Reply
RunnerSignals
RunnerSignals Jun. 2 at 8:56 PM
Comeback Kings $QBTS $JBLU $QUBT $ALEC $FROG dipped hard midday but stormed back strong into the close. Nice turnaround
0 · Reply
TimRegan_WTR
TimRegan_WTR May. 29 at 5:50 PM
$ABBV $ALEC $DNLI $NVS $TAK
0 · Reply
research_WTR
research_WTR May. 29 at 5:42 PM
TREM2 Agonists: A New Frontier in Neurodegeneration Despite past clinical setbacks, Sanofi’s $470–$600M acquisition of Vigil Neuroscience signals renewed confidence in TREM2 as a key neuroinflammation target in Alzheimer’s and other disorders. 🔹 TREM2 helps microglia clear toxic proteins and regulate inflammation in the CNS 🔹 Past mAb candidates (ALEC/ABBV, DNLI) failed in trials due to lack of efficacy or safety concerns 🔹 Vigil’s oral TREM2 agonist (VG-3927) showed strong Phase 1 data and heads to Phase 2 in 2H25 🔹 Sanofi’s support may reshape the future of microglia-targeted neurotherapies Subscribe at our website to follow along with Robert Sassoon! $ALEC $ABBV $DNLI $TAK $NVS
0 · Reply
revueltoL
revueltoL May. 28 at 4:23 PM
$ALEC this will be huge, not ‘yuuuge’ as T says..the ‘real’ huge..
0 · Reply
RobbyAxelrod1
RobbyAxelrod1 May. 28 at 2:57 PM
$ALEC In phase 3 results 4th qtr.
0 · Reply
revueltoL
revueltoL May. 22 at 8:42 PM
$ALEC $3 per share is cheap…it’s up to you to decide if it’s too late to chase. I am not expecting a gradual, organic move here…I am anticipating a gap up.”
0 · Reply
jdlman
jdlman May. 22 at 4:11 PM
$ALEC to late to chase ? Looks attractive
1 · Reply
BioStick123
BioStick123 May. 22 at 4:01 PM
$ALEC entered
0 · Reply
tariq7863a
tariq7863a May. 22 at 12:22 PM
$ALEC soon 1.25 don't be bag holders
1 · Reply
Carl_K
Carl_K May. 22 at 4:53 AM
$SNY $VIGL $INMB $ALEC $DNLI Sanofi - Vigil buyout, ~400% premium, TREM2 / microglia modulation for AD, VG-3927 is Phase 2-ready, $470 million deal. Microglia and brain immune cell modulation are the important targets here. Cfr. my blog on them from 2022. If not mistaken, TREM2 is a target that's failed to show substantial impact so far. Alector and Denali (listed as competitors in INmune's 10K) were leaders in that regard. Difficulty: you're manipulating cells with very complex behaviors (microglia) simply because TREM2 appears implicated in CNS diseases. https://www.thetyp.com/post/the-10-billion-unicorn-in-inmune-bio-it-s-the-micro-glia-stupid
3 · Reply
theBigDollarski
theBigDollarski May. 20 at 5:32 PM
$ALEC goodbye Mr. Spaulding.....even at 3.55 it trades for cash
0 · Reply
revueltoL
revueltoL May. 19 at 10:10 PM
$ALEC more like a slingshot straight to $10..
0 · Reply
Paulfrench
Paulfrench May. 19 at 7:23 AM
$ALEC Here's a chart with plenty of bullish signals. A great buying opportunity at $1.08 in my opinion!
0 · Reply
perchedcats
perchedcats May. 16 at 7:34 PM
$ALEC nice going from the all time low a few weeks ago. still plenty of room to rise in anticipation of ph3 readout
0 · Reply